Company Information

  

Address: 201 MISSION STREET, SUITE 2375  
City: SAN FRANCISCO 
State: CA 
Zip Code: 94105 
Telephone: 415-896-5081 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi (crofelemer) product is approved by the U.S. Food and Drug Administration ("FDA") for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In 1 -------------------------------------------------------------------------------- Table of Contents the field of animal health, we are focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-51.75NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.28Total Liab/Total Assets0.60
Net Inc/Total Assets-0.50Total Liab/Inv Cap1.16
Net Inc/Inv Cap-0.96Total Liab/Comm Equity0.33
Pretax Inc/Net Sales-8.06Interest Coverage Ratio-28.06
Net Inc/Net Sales-5.04Curr Debt/Equity0.31
Cash Flow/Net Sales-2.25LTD/Equity0.64
SG&A/NetSales3.29Total Debt/Equity0.95
Asset Utilization   Liquidity  
Net Receivables Turnover11.27Quick Ratio0.11
Inventory Turnover0.71Current Ratio0.25
Inventory Day Sales0.00Net Rec/Curr Assets0.12
Net Sales/Work Cap-0.38Inv/Curr Assets0.55
Net Sales/PP&E3.57  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.80 1.54 1.10 0.90
Cost of Goods Sold 0.46 0.63 0.21 0.02
Selling & Admin Exps 4.71 4.88 3.73 2.30
Operating Income -5.13 -20.68 -7.34 -2.35
Interest Exp 0.60 0.41 0.46 0.16
Pretax Income -5.70 -21.20 -7.43 -1.81
Other Income 0.03 -0.11 0.37 0.70
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -5.70 -20.21 4.76 -1.81

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 7.81 0.76 0.72 2.76
Receivables - Total 0.37 0.47 0.78 0.43
Inventories - Total 2.33 2.07 1.83 0.40
Total Current Assets 10.87 3.80 4.24 3.96
Net Property, Plant & Equipment 1.21 1.22 0.84 0.86
Total Assets 50.27 43.63 59.99 4.94
Liabilities        
Accounts Payable 4.83 9.55 9.78 4.30
Debt in Current Liabilities 4.36 5.43 5.03 3.87
Total Current Liabilities 9.38 15.39 16.03 10.36
Long-Term Debt 10.88 10.98 11.16 0.84
Total Liabilities 20.26 26.37 28.18 11.21
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA 0.00 0.00 0.00
Common Stock 0.02 0.01 0.01 0.00
Retained Earnings -68.10 -62.40 -42.20 -46.96
Treasury Stock NA NA NA NA
Total Stockholders' Equity 21.01 17.26 31.81 -6.27
Total Liabilities and Stockholders' Equity 41.27 43.63 59.99 4.94

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -9.62 -5.33 -3.03 -1.18
Net Cash Provided by Investing Activities -0.01 0.26 -2.06 0.51
Net Cash Provided by Financing Activities 16.68 5.37 2.55 2.71

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20140.00-8.61--
12/20150.26-16.29--
12/20160.14-14.73--
12/20174.36-21.97--
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18182,42827.80




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.